Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  

With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.  

Kleiner Perkins

Celgene

DAG Ventures

Domain Associates

EcoR1 Capital

Alexandria

Amgen Ventures

Atara Biotherapeutics

Today Atara announced the publication of the pivotal ALLELE tab-cel® study data in patients with relapsed or refractory Epstein-Barr virus (#EBV) positive post-transplant lymphoproliferative disease (#PTLD) in The Lancet Oncology, representing the first Phase 3 results published for an #allogeneic #Tcell therapy. 

➡Press release: https://bit.ly/4bkXbT1 

It was a pleasure highlighting the latest developments and potential of Atara's #allogeneic #CART programs for hematological malignancies and autoimmune diseases at #JPM24. https://bit.ly/3vxNksE

Next week, our CEO Pascal Touchon is heading to San Francisco to share Atara's latest pipeline progress & key development milestones at the J.P. Morgan Annual Healthcare Conference on Thursday, January 11 at 9:45 a.m. PT: https://bit.ly/3H8hXrd 

At this year's American Society of Hematology Annual Meeting, Atara will present positive preclinical data on ATA3431, our investigational next-generation #allogeneic CD20/CD19-targeted #CAR #EBV T-cell therapy for the treatment of B-cell malignancies. For more: https://bit.ly/3GA8b0O #ASH23  

Domain Not Resolving

DNSSEC

reCAPTCHA

CloudFront

PostalAddress Schema

Microsoft

Gravity Forms

Corporation Schema

Chief Scientific Officer

Cokey Nguyen

Assistant General Counsel, Contracts

John Chao

Chief Operations Officer

Joseph Newell

Chief Commercial Officer

Kristin Yarema, Ph.D.

Head of Development, Chief Medical Officer

Manher Joshi

President and CEO/ Member of the Board of Directors

Pascal Touchon

Senior Vice President, Chief People Officer

Steve Bertram

VP Clinical Operations

Betty Mendes

SVP and Head of Business Development and Corporate Strategy

Dan Maziasz

Vice President, Global Compliance and Privacy

Danielle Graves

Beth Seidenberg

Greg Ciongoli

Ameet Mallik

Matthew Fust

Carol Gallagher

Charlene Banard

Jill Henrich

SVP, Global Regulatory Affairs

Maclovia Zelaya

Executive Assistant to Chief Executive Officer

AJ Joshi

Head of Clinical Development and Chief Medical Officer

Utpal Koppikar

Chief Financial Officer & Senior Vice President

Christopher Haqq

Executive Vice President of Research & Development & Chief Scientific Officer

Joe Newell

SVP, Chief People Officer

Therapeutics Companies With More Than $1M in Revenue (Top 10K)

California Health Care Companies (Top 10K)

West Coast Health Care Companies (Top 10K)

Western US Public Companies With More Than 10 Employees

Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Post-IPO Equity - Atara Biotherapeutics

Venture Round - Atara Biotherapeutics

Series B - Atara Biotherapeutics

South San Francisco

California

United States

North America

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Atara Biotherapeutics reports Q2 EPS ($3.10), consensus ($1.56)

FDA accepts Atara Biotherapeutics’ Tab-Cel for priority review

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Atara Biotherapeutics' Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare ...

Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split

Atara Biotherapeutics trading halted, news pending

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the ...

Switzerland

Europe

India

Asia

Serbia

Pakistan

HTML5

Google Tag Manager

Modernizr

F5 NGINX

Facebook Comments

Google Analytics

DigiCert

Office 365

Adobe Flash

Microsoft Outlook

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Oct 31, 2024 9:55 AM	5c1936b2
crunchbase profile	general	Oct 31, 2024 10:06 AM	2666ebe5
li profile	general	Feb 1, 2024 3:21 PM	4928fd64
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	8fca74b3
peers	general	Feb 1, 2024 3:21 PM	79530274
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ATARABIO

Atara Biotherapeutics Inc

Last Close

10.61

22/11 21:00

Market Cap

44.24M

Beta: -

Volume Today

65.66K

Avg: -